Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy


This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with persistent severe peanut allergy. This is a proof-of-concept trial in which the primary outcome will be the suppression of the initial peanut specific IgE surge during OIT, which is used as a proxy outcome of peanut allergy remission. Adolescents and adults with persistent severe peanut allergy (n=14) will be randomized to either abatacept or placebo at a ratio 1:1 for a total period of 24 weeks. Peanut oral immunotherapy will be initiated the day following the first administration of the investigational product. Sustained tolerance to peanut will be assessed at 36 weeks.

Full Title of Study: “A Double-blind Randomized Controlled Trial of 6-month of Abatacept vs Placebo as Adjuvant to Peanut Oral Immunotherapy to Induce Immunologic Changes in Patients With Severe Persistent Peanut Allergy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2022


  • Drug: Abatacept
    • 24 week treatment of IV abatacept following recommended dosages from the monograph
  • Other: Peanut oral immunotherapy
    • Peanut oral immunotherapy, following a patient-driven protocol, starting 24 to 72h after the first administration of abatacept or placebo.

Arms, Groups and Cohorts

  • Experimental: Abatacept
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Peanut specific/total IgE at week 24
    • Time Frame: 24 weeks
    • Relative change in peanut specific/total IgE from baseline to week 24

Secondary Measures

  • Peanut-specific IgG4/IgE ratio at week 24
    • Time Frame: 24 weeks
    • Relative change in peanut-specific IgG4/IgE ratio from baseline to week 24
  • Peanut-specific IgG4 at week 24
    • Time Frame: 24 weeks
    • Absolute change in peanut-specific IgG4 from baseline to week 24
  • Sustained tolerance
    • Time Frame: Assessed between week 36 and week 48
    • Maximum period of avoidance after which a oral food challenge with 300 mg peanut protein is still tolerated
  • Food dosing reactions
    • Time Frame: 48 weeks
    • Mean cumulative function of food dosing allergic reactions
  • Desensitization
    • Time Frame: 36 weeks
    • Highest tolerated dose on an oral food challenge at week 36
  • Desensitization speed
    • Time Frame: 36 weeks
    • Time from the onset of oral immunotherapy to the maintenance dose of 300mg
  • Adverse events
    • Time Frame: 48 weeks
    • Overall rate of adverse events

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subjects 14 to 50 years old at screening visit – History of IgE mediated allergy to peanut protein – ImmunoCAP IgE level > 50 kU/L for peanut; – Total IgE level < 5000 kU/L – Willing to comply to all study requirements during participation in the study; Exclusion Criteria:

  • Previous adverse reactions to abatacept; – Known hypersensitivity to abatacept or any of its components; – Patients at risk of sepsis, such as immunocompromised or HIV positive; – Patient undergoing a treatment with any other biologic agent; – Uncontrolled asthma; – Unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis, or other chronic or immunological diseases that, in the judgment of the investigator, might interfere with the evaluation, administration of the test drug or pose additional risk to the subject (e.g., gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease); – Current users of oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants or beta-blocker – Concurrent/prior use of immunomodulatory therapy (within 6 months); – A diagnosis of eosinophilic esophagitis, eosinophilic colitis, or eosinophilic gastritis; – Pregnant or breastfeeding women;

Gender Eligibility: All

Minimum Age: 14 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Philippe Bégin
  • Collaborator
    • Centre hospitalier de l’Université de Montréal (CHUM)
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Philippe Bégin, Associate professor – St. Justine’s Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.